Nigel Key
University of North Carolina at Chapel Hill
H-index: 89
North America-United States
Top articles of Nigel Key
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Plasma kallikrein supports FXII-independent thrombin generation in mouse whole blood | Blood Advances | Jun Wan Sophia Dhrolia Rohan R Kasthuri Yuriy Prokopenko Anton Ilich | 2024 |
P246: Challenges in establishing best practices for gene therapy informed consent for hemophilia A/B | Genetics in Medicine Open | Kristy Lee Callie Berkowitz Kristi Jackson Brenda Nielsen Patrick Ellsworth | 2024/1/1 |
Biomarkers of bleeding and venous thromboembolism in patients with acute leukemia | Journal of Thrombosis and Haemostasis | Yohei Hisada Sierra J Archibald Karan Bansal Yanjun Chen Chen Dai | 2024/4/2 |
Bleeding disorder of unknown cause & unclassified bleeding disorders at US hemophilia treatment centers | Research and Practice in Thrombosis and Haemostasis | Callie Berkowitz Kristi Kirkland Alice Ma Nigel S Key | 2024/1 |
Emicizumab promotes factor Xa generation on endothelial cells | Journal of Thrombosis and Haemostasis | Ammon M Fager Patrick Ellsworth Nigel S Key Dougald M Monroe Maureane Hoffman | 2024/3/8 |
Fewer severe infections with tranexamic acid in patients with hematologic malignancies | Research and Practice in Thrombosis and Haemostasis | Jacqueline N Poston Siobhan P Brown Anton Ilich Amy Sarah Ginsburg Heather Herren | 2024/3/1 |
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial | The Lancet Haematology | Michiel Coppens Steven W Pipe Wolfgang Miesbach Jan Astermark Michael Recht | 2024/3/1 |
Etranacogene Dezaparvovec Shows Sustained Efficacy and Safety in Adult Patients With Severe or Moderately Severe Haemophilia B 3 Years After Administration in the HOPE-B Trial | Hämostaseologie | S Pipe P van der Valk P Verhamme P Kampmann F Leebeek | 2024/2 |
HTRS2023. P2. 10 Structured assessments and clinical phenotypes in bleeding of unknown cause | Research and Practice in Thrombosis and Haemostasis | Callie Berkowitz Kristi Kirkland Alice Ma Nigel Key | 2023/8/1 |
OC 64.3 Biomarkers of Bleeding and Venous Thromboembolism in Patients with Acute Leukemia | Research and Practice in Thrombosis and Haemostasis | Y Hisada S Archibald K Bansal Y Chen S Dwarampudi | 2023/10/1 |
Long-Term Bleeding Protection, Sustained FIX Activity, Reduction of FIX Consumption and Safety of Hemophilia B Gene Therapy: Results from the HOPE-B Trial 3 Years after … | Blood | Steven Pipe Paul van der Valk Peter Verhamme Peter Kampmann Frank WG Leebeek | 2023/11/28 |
Plasma Kallikrein as a forgotten clotting factor | Katherine J Kearney Henri MH Spronk Jonas Emsley Nigel S Key Helen Philippou | 2023/4/18 | |
Gene therapy with etranacogene dezaparvovec for hemophilia B | New England Journal of Medicine | Steven W Pipe Frank WG Leebeek Michael Recht Nigel S Key Giancarlo Castaman | 2023/2/23 |
Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review | Jasmin Jo Maria Diaz Craig Horbinski Nigel Mackman Stephen Bagley | 2023/8/1 | |
OC 52.1 Assessing the Safety Profile of AMT-060 and Etranacogene Dezaparvovec Gene Therapies Across Clinical Trials in People with Severe/Moderately Severe Hemophilia B | Research and Practice in Thrombosis and Haemostasis | W Miesbach M Recht N Key R Guillen-Gonzalez K Sivamurthy | 2023/10/1 |
Hypertonicity and/or Acidosis Induce Marked Rheological Changes Under Hypoxic Conditions in Sickle Trait Red Blood Cells | Blood | Patrick Ellsworth Izabela Pawlinski Rachel Sielaty Anton Ilich Chatphatai Moonla | 2023/11/28 |
Durability of Factor IX activity and bleeding rate in people with severe or moderately severe haemophilia B after long-term follow-up in the phase 1/2 Study of AMT-060, and … | Hämostaseologie | W Miesbach M Recht N Key K Sivamurthy EP Monahan | 2023/2 |
Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell disease | Blood | Erica M Sparkenbaugh Michael W Henderson Megan Miller-Awe Christina Abrams Anton Ilich | 2023/4/13 |
Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update | Journal of Clinical Oncology | Nigel S Key Alok A Khorana Nicole M Kuderer Kari Bohlke Agnes YY Lee | 2023/6/1 |
OC 52.5 Phase 3 HOPE-B Trial of Etranacogene Dezaparvovec in Severe/Moderately Severe Hemophilia B: A Post Hoc Responder Analysis of Participants Who Received Full Dose and … | Research and Practice in Thrombosis and Haemostasis | S Pipe F Leebeek M Recht N Key S Lattimore | 2023/10/1 |
